“…Varying the substituents at the heterocycle (triazine) allows to change the properties of the compound [8] with potentially advantageous medical effects. Substance (a) was synthesised, investigated, and subsequently approved for medical use in the 1980s as an antineoplastic agent for the treatment of ovarian, breast, lung, kidney, liver cancers and for the prevention of regional metastasis in oral cancer [9][10][11][12]. In [13] it was shown that substance (a) is effective against abdominal carcinomatosis in animals.…”